Literature DB >> 3320537

The structure and function of progesterone receptors in breast cancer.

K B Horwitz1.   

Abstract

This paper is a review of the clinical role of progesterone receptors (PR) in the management of breast cancer, and the use of synthetic progestins in treatment of the metastatic disease. Also reviewed are our basic molecular studies dealing with the structure of human breast cancer PR, focusing on the two hormone binding proteins (the A- and B-receptors) and the role of phosphorylation. A model for the structure of PR and their subcellular compartmentalization following hormone treatment is presented.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3320537     DOI： 10.1016/0022-4731(87)90339-6

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN： 0022-4731            Impact factor:   4.292


  7 in total

1.  Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

Authors:  Dong Zhou; Terry L Sharp; Nicole M Fettig; Hsiaoju Lee; Jason S Lewis; John A Katzenellenbogen; Michael J Welch
Journal:  Nucl Med Biol       Date:  2008-06-30       Impact factor: 2.408

2.  Organisation of the entire rabbit progesterone receptor mRNA and of the promoter and 5' flanking region of the gene.

Authors:  M Misrahi; H Loosfelt; M Atger; C Mériel; V Zerah; P Dessen; E Milgrom
Journal:  Nucleic Acids Res       Date:  1988-06-24       Impact factor: 16.971

3.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

4.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Authors:  R Poulin; D Baker; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

5.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; D Baker; D Poirier; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-03       Impact factor: 4.872
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.